** Shares of eFFECTOR Therapeutics EFTR.O fall 78.6% to a
record low of $3.53
** Co says that it will discontinue development of its
experimental therapy tomivosertib in non-small cell lung cancer
(NSCLC)
** EFTR says that while there was modest activity from
tomivosertib in the mid-stage study, it does not see an obvious
path forward to continue development
** Co says there were 67% treatment emergent adverse events
for tomivosertib in combination with Merck's MRK.N cancer drug
Keytruda vs 37% for placebo plus Keytruda
** NSCLC is the most common form of lung cancer
** YTD, stock down ~69.8%
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))